Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Apr
30
Today In Oncology
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
MIBC Pembrolizumab With Trimodal Therapy for Bladder Preservation
Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC
Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo